Literature DB >> 7740492

Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.

J Amiral1, F Bridey, M Wolf, C Boyer-Neumann, E Fressinaud, A M Vissac, E Peynaud-Debayle, M Dreyfus, D Meyer.   

Abstract

As heparin-PF4 (H-PF4) complexes are the target for antibodies associated to heparin-induced thrombocytopenia (HIT), an ELISA has been developed and optimised for testing antibodies binding to H-PF4. This test was consistently negative in 50 healthy subjects (A492 < 0.3) and 35 patients with other causes of thrombocytopenia (A492 < 0.5). In contrast, 43 out of 44 HIT patients showed antibodies to H-PF4 (A492 = 1.70 +/- 0.81) including 5 patients with a negative platelet aggregation test. In one patient with HIT, antibodies to H-PF4 were already present at day 7, whereas platelet counts dropped < or = 100 x 10(9)/l only at days 11-12. Surprisingly, among 41 patients under heparin for > 7 days, 5 showed antibodies to H-PF4, without HIT. These findings underline the major interest of this ELISA for the early diagnosis of HIT. We also showed that LMWH as well as other sulphated polysaccharides can bind to HIT antibodies in the presence of PF4 and that their reactivity is dependent on the molecular weight and the sulphation grade. The mechanism for HIT involves platelet PF4 receptors which bind the macromolecular H-PF4 complexes formed in the presence of a well defined heparin/PF4 ratio.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740492

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  27 in total

Review 1.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 2.  Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants.

Authors:  Albrecht Leo; Susanne Winteroll
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 3.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors.

Authors:  J Llevadot; S A Coulter; R P Giugliano
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

5.  Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.

Authors:  Rustem I Litvinov; Serge V Yarovoi; Lubica Rauova; Valeri Barsegov; Bruce S Sachais; Ann H Rux; Jillian L Hinds; Gowthami M Arepally; Douglas B Cines; John W Weisel
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

Review 6.  Heparin induced thrombocytopenia: diagnosis and management update.

Authors:  I Ahmed; A Majeed; R Powell
Journal:  Postgrad Med J       Date:  2007-09       Impact factor: 2.401

Review 7.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

8.  Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature.

Authors:  Indraneel Datta; Chad G Ball; Lucas Rudmik; S Morad Hameed; John B Kortbeek
Journal:  J Trauma Manag Outcomes       Date:  2010-01-06

Review 9.  Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).

Authors:  Zheng Cai; Zhiqiang Zhu; Mark I Greene; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2016-03-09       Impact factor: 9.754

10.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.